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D5 DOPAMINE RECEPTOR REGULATION OF
REACTIVE OXYGEN SPECIES PRODUCTION AND
BLOOD PRESSURE IN MICE
Zhiwei Yang, Peiying Yu, Laureano D. Asicol, Zheng Wang, John E
Jones, David R. Sibley, Pedro A. Jose. Department of Pediatrics and
Physiology and Biophysics, Georgetown University Medical Center,
Washington, DC; National Institute of Neurological Disorders and
Stroke, National Institutes of Health, Bethesda, MD.
D1-like receptors have novel antioxidant properties in rat renal vascular
smooth muscles, but the D1-like receptor (D1 or/or D5) involved is not
known. The D5 receptor inhibits phospholipase D (PLD) activity in CHO
and HEK-293 cells, expressing the human (h)D5 receptor (hD5R). Be-
cause phosphatidic acid, a product of PLD, activates NADPH oxidase,
we hypothesized that the hD5R inhibits NADPH oxidase activity, and
thus, the production of reactive oxygen species (ROS). These effects may
be important in the hypertension that develops in D5R deficient mice.
Systolic blood pressures (SBP, mm Hg), measured from the femoral
artery under pentobarbital anesthesia, are higher in D5R deficient
(D5/) (SBP1364, n70) than in wild type mice (D5/)
(SBP1031, n67, P0.05). Tempol (10 mg/kg IV), a superoxide
dismutase mimetic, acutely decreases blood pressure in pentobarbital-
anesthetized D5/ but not in D5/ mice (D5/, SBPbefore,
1342, after, 1205, n5; D5/, SBPbefore, 1031, after, 1003,
n9, p0.05). The expressions of p47phox, one cytosolic, and gp91phox,
one membrane component of NADPH oxidase, are increased in D5/
mice kidney compared with D5/ mice (P0.05, n3/group). In
HEK-293 cells expressing hD5R(HEK-hD5R) but not D1R, the D1/D5
agonist, fenoldopam (FEN), decreases NADPH oxidase activity, in a
time- and dose-dependent manner (FEN, 5 M, 30 min  502 light
units/g protein; vehicle 361, P0.05, n3/group). FEN also inhib-
its O2 by 58% (FEN, 5 M  425 nmol O2 /106 cells; vehicle
1014, P0.05, n8/group), and H2O2 production by 36% (FEN, 1
M  281.4 nmol H2O2/hour/106 cells; vehicle 182.2 , P0.05,
n4/group). cAMP/PKA does not mediate the inhibitory effects of the
D5R on ROS production; the adenylyl cyclase inhibitor, SQ22536, and
PKA inhibitors, H-89, R-8-Piperidino-cAMPs and Rp-cAMPs, do not
prevent the D5R action. The D5R also cofractionates with gp91phox and
p67phox , in HEK-hD5R and rat renal proximal tubule cells (RPTC). In
RPTCs, the D5R but not D1R is linked to and co-fractionates with
gp91phox. We suggest that the D5R inhibits NADPH oxidase activity,
directly or indirectly, via PLD, but independent of PKA, decreases ROS
production, and may explain the antihypertensive function of D5Rs.
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THE ROLE OF RENAL SUPEROXIDE DISMUTASE
(SOD) ON THE SLOW PRESSOR EFFECTS OF
ANGIOTENSIN II
W J Welch, G Solis, T Chabrashvili, C S Wilcox. Cardiovascular-
Kidney Institute, Georgetown University, Washington, DC.
Low doses of Ang II increased BP and oxidative stress after 14 days in
rats. However, Ang II downregulated renal extracellular Cu-Zn-SOD
(ECSOD), a major antioxidant defense system, without alteration of
Mn-SOD or intracellular SOD (IC-SOD). We tested the hypothesis that
in the absence of EC-SOD, Ang II causes even greater oxidative stress.
We used EC-SOD wild type (WT) and knockout (KO) mice, treated with
a slow pressor dose of Ang II (400 ng/kg/min) or vehicle for 2 weeks.
Oxidative stress was apparent in the KO mice, since the excretion of
8-PGF2 was higher in KO (WT: 1.30.1 KO: 2.20.3 pg/day,
p0.01), however Ang II increased 8-isoPGF2 only in WT (WT:
2.20.2, p0.01;KO: 2.00.2,ns). Further, renal cortex superoxide
(O2-) concentration was higher in KO mice and also was increased by
Ang II only in WT (WT:7.80.4 KO: 11.81.2mmol/mg prot,p0.01;
WTAngII: 12.51.4, p0.05; KOAng II: 12.91.3mmol/mg prot).
Excretion of malondialdehyde (MDA) was also higher in KO and was
increased by Ang II only in WT (WT: 323; KO: 608 nmol/day,
p0.01; WTAng II: 605 KOAng II: 547, ns). Na excretion,
GFR, RBF and FF were not different between WT and KO and Ang II
had no effect on each. Ang II increased conscious MAP similarly in both
groups (WT 153 vs KO 163 mmHg, ns). Under anesthesia MAP
was also similar (WT Ang II: 983 vs KO Ang II: 1023 mmHg, ns).
Renal mRNA expression for Mn- and IC-SOD did not differ between WT
and KO. In WT mice the expression of EC-SOD was lower in Ang II
treated mice (1.6 fold). However, after Ang II, expression of IC-SOD
mRNA was higher in KO (WT: 0.9 vs KO: 1.9 fold, p0.01) but
Mn-SOD was not different. In conclusion, EC-SOD KO mice have
greater renal oxidative stress. However, Ang II failed to generate further
oxidative stress or higher MAP in the absence of EC-SOD in knockout
mice, possibly due to upregulation of renal IC-SOD, which may defend
against the increased production of superoxide.
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RENAL ENDOTHELIN RECEPTOR TYPE B
UPREGULATION IN RATS WITH LOW OR HIGH
RENIN HYPERTENSION
Noureddine Brakch, Saad Abdel-Sayed, Flore Allemandou, Hans R
Brunner, Juerg Nussberger. Hypertension Division, University
Hospital, Lausanne, Switzerland.
Endothelin-1 (ET-1) is a potent renal and systemic vasoactive peptide. It
acts through ETA and ETB receptors. We investigated density and
subtype distribution of ET-1 receptors in hearts and kidneys of normo-
tensive and hypertensive rats.
Five groups of uninephrectomized Wistar rats were put on a low salt
diet for six weeks. During this period, three groups of rats drank tap water
and two groups received saline. One group of each regimen received
DOCA subcutaneousely (1.6 mg/day). The fifth group of rats had the left
renal artery clipped to induce 1K1C hypertension. At 6 weeks, mean
arterial pressure (MAP) was recorded in conscious rats via a femoral
artery catheter. Binding assays using 125I-ET-1 were carried out on
membrane preparations in the presence and absence of the ETA receptor
antagonist FR139317.
On tap water, MAP was at 121.83.3 mmHg and DOCA or saline did
not raise this MAP. On DOCA-salt and in 1K1C rats, MAP was increased
to 154.55.8 mmHg (p0.001) and 218.410.5 (p0.001) mmHg,
respectively. ET receptor subtypes were not equally expressed in the
heart and the kidney: ETA was predominantly expressed in the heart,
whereas ETB was predominant in the kidney. Both hypertensive models,
the DOCA-salt and the 1K1C rats showed further significant changes: i)
Cardiac weight index compared to controls of 2.490.06 mg/g was
higher (p0.001) at 3.890.10 and 4.860.18 mg/g in DOCA-salt and
1K1C hypertension, respectively, and kidney weight index compared to
controls of 4.780.22 mg/g was higher at 10.100.54 mg/g in DOCA-
salt (p0.001) but tended to be below controls in 1K1C rats. ii) In the
kidneys, the density of the ETB receptor subtype was upregulated in
DOCA-salt and 1K1C rats from 1608 to 21712 and 1902 fmol/mg
(p0.05), respectively, and ETA tended to be downregulated. iii) Plasma
renin activity was decrased in DOCA-salt rats from 173 to 0.170.01
ng/ml/h and increased in 1K1C rats on low salt diet to 305 ng/ml/h
(p0.001).
We conclude that upregulation of the ETB receptor mediating vaso-
dilation and downregulation of the ETA receptor mediating vasoconstric-
tion is compatible with a mainly renal counterregulatory effect of
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endothelin-1 to hypertension. This counterregulation may occur in both
low and high renin models of hypertension.
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LEFT VENTRICULAR HYPERTROPHY IN CHRONIC
KIDNEY DISEASE
Ernesto Paoletti, Paolo Cassottana, Diego Bellino, Beatrice Damasio,
Giuseppe Cannella. Divisione di Nefrologia, Dialisi e Trapianto,
Azienda Ospedale S.Martino, Genova, Italy; Divisione di Cardiologia,
Azienda Ospedale S.Martino, Genova, Italy.
Chronic kidney disease (CKD) is defined as the presence of kidney
damage or decreased renal function for at least three months, and is
associated with high prevalence of cardiovascular complications. While
left ventricular hypertrophy (LVH) is the single strongest predictor of
cardiovascular morbidity and mortality in dialysis population, very few
studies are available on LVH prevalence and predictors in CKD.
Thus, we investigated 274 pts (183 men and 91 women, aging 17-78
yrs) referred to our outpatient clinic for CKD, during a three years period.
All patients had blood pressure (BP) assessed by 24 hrs ABPM, left
ventricular mass index (LVMi) measured by M-Mode echocardiography,
creatinine clearance (CrCl) determined by Cockroft formula, hemoglobin
(Hb), biochemical profile, and daily urinary protein excretion (UPROT) by
routine methods.
The values for 24 hr systolic (S), diastolic (D) BP and pulse pressure
(PP) were 14616, 8811 and 5614 mmHg respectively. The preva-
lence of arterial hypertension (BP140/90 mmHg) was 46%. Non dip-
ping prevalence was 68%. CrCl was 4734ml/min, Hb 11.6 2.4 g/dl
and proteinuria ranged from 0 to 7.6 g/day. LVMi was 15649 g/m2 bsa,
and the prevalence of LVH (LVMi125 g/m2 bsa) was 71%. A direct
relationship was demonstrated between LVMi and PP (p.0006) and age
(p.008) respectively , while LVMi was inversely related to CrCl
(p.02) and Hb (p.04). By stepwise regression analysis study, male
gender (beta 31.12), Cr Cl (beta .25) and PP (beta 1.04) resulted as
significant predictors of LVH (p.00001), and this model accounted for
28% of LVMi variance.When we considered the 191 pts with 3 to 5
stages CKD (Cr Cl 60 ml/min), male gender (beta 28.85), Cr Cl (beta
.51) and PP (beta 1.21) were again the predictors of LVH (p .00001),
while age (beta 1.06), male gender (beta 39.82), daytime systolic BP
(beta .63) and UPROT (beta 4.10) predicted LVH (p .00001) in the 83
subjects with normal renal function (CKD stages 1 and 2).
In conclusion the prevalence of LVH in CKD is much higher than
previously reported. Together with unmodifiable factors like age and
gender, BP load is the most important factor associated with LVH, while
the role of anemia seems to be less important. Moreover LVH is asso-
ciated with urinary protein excretion, a strong predictor of cardiovascular
disease in hypertensive patients, and LVMi progressively increases as
renal function worsens.
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URIC ACID, NEPHRON NUMBER AND THE
PATHOGENESIS OF ESSENTIAL HYPERTENSION
Daniel I. Feig, Takahiko Nakagawa, S. Ananth Karumanchi, Duk-Hee
Kang, Richard J. Johnson. Pediatrics, Renal Section, Baylor College
of Medicine, Houston, TX; Medicine, Division of Nephrology,
University of Florida Scholl of Medicine, Gainesville, FL; Medicine,
Division of Nephrology, Beth Israel Medical Center, Boston, MA;
Medicine, Division of Nephrology, Ewha University College of
Medicine, Seoul, Korea.
Genetic, physiologic and epidemiological studies provide clues but no
clear elucidation of the etiology of essential hypertension. We have
combined epidemiological methods, clinical trials, animal models and
tissue culture investigations to demonstrate that uric acid may be a
unifying link between several disparate theories of the origins of essential
hypertension. In retrospective chart review of 265 newly diagnosed
children with hypertension, we evaluated parental history, subject birth
weight and serum uric acid. In an open label cross over trial we treated
children with confirmed essential hypertension with allopurinol as a
single anti-hypertensive agent. In tissue culture experiments we evalu-
ated the effect of uric acid on glomerular endothelial proliferation by
3H-thymidine uptake. Elevation of serum uric acid is closely associated
with pediatric onset essential hypertension (r0.80, p0.00001). Mater-
nal history of hypertension was preferentially associated with essential
but not secondary or white coat hypertension (41.3% vs. 26.9% and
27.3%, respectively, p0.009), as was lower birth weight (mean of
3070g vs. 3498g and 3512g, respectively, p0.005). Uric acid (5mg/dl)
added to the growth medium of glomerular endothelial in culture cells
inhibited 3H-thymidine uptake by 23% (p0.03). These data, combined
with our recent animal model evidence of uric acid inducing renal
arteriolopathy and hypertension (through downregulatioin of eNOS and
activation of the renin angiotensis system), the association of essential
hypertension with congenitally lower nephron number, and the increased
risk of hypertension in the children of preeclamptic mothers suggest that
maternal uric acid may inhibit fetal nephron development. We propose
the following model for the involvement of uric acid in decreased
nephron number and childhood onset essential hypertension.
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INTENSIVE BLOOD PRESSURE CONTROL WITH
VALSARTAN DECREASES PROGRESSION OF
URINARY ALBUMIN EXCRETION IN
NORMOTENSIVE TYPE 2 DIABETIC PATIENTS
Raymond O Estacio, Anne L Esler, Rita A Lundgren, Robert W
Schrier. Internal Medicine, Denver Health, Denver, CO; Colorado
Prevention Center, Denver, CO; Department of Medicine, University
of Colorado Health Sciences Center, Denver, CO.
Diabetic nephropathy is the most common cause of renal failure in the
US and is associated with cardiovascular morbidity and mortality. Mul-
tiple studies have demonstrated the benefits of blood pressure (BP)
therapy on diabetic nephropathy but have focused on hypertensive dia-
betic patients with either micro- or overt albuminuria. There is a paucity
of data regarding the effects of aggressive BP treatment in normotensive
type 2 diabetic patients. The current study was designed to evaluate the
effects of aggressive BP control with valsartan in a normotensive type 2
diabetic population with normoalbuminuria and microalbuminuria.
The study was a single-center, prospective, randomized clinical trial
based in Denver, Colorado evaluating the effects of intensive versus
moderate BP control on type 2 diabetic patients. We randomized 129
type 2 diabetic patients with a BP of 140/80-90 mm Hg without overt
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